Y. Inui

First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab

First-week expansion of activated peripheral B-cell subsets after nivolumab plus ipilimumab was associated with subsequent severe irAEs, which support future studies of early B-cell monitoring within integrated multimarker assessments of irAE risk.